KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Non Operating Income (2017 - 2025)

Historic Non Operating Income for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to -$219000.0.

  • Bionano Genomics' Non Operating Income rose 6857.96% to -$219000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year increase of 9020.53%. This contributed to the annual value of -$10.1 million for FY2024, which is 5071.47% up from last year.
  • Bionano Genomics' Non Operating Income amounted to -$219000.0 in Q3 2025, which was up 6857.96% from $953000.0 recorded in Q2 2025.
  • Over the past 5 years, Bionano Genomics' Non Operating Income peaked at $5.4 million during Q1 2025, and registered a low of -$22.3 million during Q4 2023.
  • For the 5-year period, Bionano Genomics' Non Operating Income averaged around -$1.3 million, with its median value being $67000.0 (2021).
  • Data for Bionano Genomics' Non Operating Income shows a peak YoY increase of 235757.58% (in 2023) and a maximum YoY decrease of 350229.01% (in 2023) over the last 5 years.
  • Bionano Genomics' Non Operating Income (Quarter) stood at $67000.0 in 2021, then surged by 877.61% to $655000.0 in 2022, then tumbled by 3502.29% to -$22.3 million in 2023, then soared by 62.27% to -$8.4 million in 2024, then surged by 97.4% to -$219000.0 in 2025.
  • Its Non Operating Income was -$219000.0 in Q3 2025, compared to $953000.0 in Q2 2025 and $5.4 million in Q1 2025.